On July 6, Moderna rose 5.13% in regular trading, trading at $84.17/share, with turnover of $351 million. The stock continues to gain momentum on optimism surrounding its seasonal flu vaccine candidate.

On the news front, Moderna's mRNA-1010 seasonal influenza vaccine candidate previously received unanimous 9-0 support from the FDA's Vaccines and Related Biological Products Advisory Committee, recommending that the benefits outweigh risks for adults aged 50 and older. The final regulatory decision is expected by August 5. While the committee recommendation is non-binding, the FDA typically follows its advisory panels. Additionally, Arete on June 29 raised its target price from $185 to $433, significantly above the consensus target of $319.37.

The company has also been repositioning itself as a platform biotech, having unveiled its in-vivo CAR-T program mRNA-6007 and multiple pipeline assets at its June 25 Science Day. Moderna recently appointed a new Chief Commercial Officer to prepare for potential launches of up to three new vaccines by 2028.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)